Nanfang Yuan Bio Completes Tens of Millions RMB Series A Financing; UK Plans to Adopt EU High-Risk IVD Common Specifications

1. Jinan to Focus on Four Strategies for Science and Technology Innovation in the Second Half of the Year

Recently, the Jinan Science and Technology Bureau held a mid-year work summary conference for the first half of 2025 and a promotion meeting for key tasks in the second half. The meeting emphasized focusing on four key areas of work: First, scientifically formulate the "15th Five-Year Plan" for scientific and technological innovation, adhering to the unity of goal-oriented and problem-oriented approaches, strengthening forward-looking thinking and strategic planning, deepening situation analysis, and scientifically setting development goals and core indicators. Second, promote the deep integration of scientific and technological innovation with industrial innovation, focus on the innovative development needs of the city's "13+34" industrial chains, support enterprises in leading the tackling of key core technologies, and promote the transformation and industrial application of major scientific and technological achievements in frontier fields in Jinan. Third, focus on optimizing the innovation and entrepreneurship ecosystem, continuously improve the tiered cultivation system for technology enterprises, strengthen the supporting role of high-level innovation platforms, and facilitate the "last mile" of technology transfer. Fourth, promote the high-quality development of the science and technology service industry, strengthen city-district cooperation and departmental collaboration, deeply implement the "Science and Technology Services for Hundreds of Enterprises" initiative, and ensure stable operation of the industry. (Zhongyuan Network)

2. Hainan Provincial Medical Insurance Bureau Issues Notice on the Implementation of Centralized Procurement for 4 Types of Vascular Interventional Medical Devices

Recently, according to the relevant regulations and work arrangements of the "Provincial Alliance Centralized Bulk Procurement Document for Vascular Interventional Medical Devices" (Procurement Document No.: LM-HD2024-01, 02, 03, 04), the Hainan Provincial Medical Insurance Bureau announced the implementation of the centralized bulk procurement results for four types of vascular interventional medical devices led by Hebei Province. Purchasing entities: All public medical institutions within the province (including military medical institutions stationed in Hainan) and all designated social medical institutions that have participated in reporting quantities must participate; other designated social medical institutions are encouraged to voluntarily participate. Procurement categories: Selected results and supply lists for four types of medical consumables including peripheral vascular interventional guiding pathways, flow-diverting dense mesh stents, intracranial balloon dilatation catheters, and peripheral vascular balloon dilatation catheters. (Hainan Provincial Medical Insurance Bureau)

3. Johnson & Johnson Medical Technologies Intensifies China Strategy

Recently, Johnson & Johnson and the Beijing Municipal Health Commission jointly announced a strategic partnership to enhance the accessibility of quality medical resources, accelerate the development of smart healthcare systems, and create a new interconnected ecosystem for healthcare services. The two parties signed a Memorandum of Strategic Cooperation, establishing the establishment of the Johnson & Johnson China Innovation Center in Beijing. As an empowerment matrix integrating "industry, academia, research, and application" by Johnson & Johnson Medical Technology in China, the Innovation Center will focus on three strategic areas: digital healthcare innovation, professional talent incubation, and clinical applications in electrophysiology. It aims to develop patient-centered solutions, improve clinical diagnosis and treatment standards, and expedite the transformation and application of advanced medical technologies. As a strategic comprehensive innovation hub of Johnson & Johnson Medical Technology, the Innovation Center will concentrate on the coordinated development of the following three key areas: a comprehensive upgrade of the Johnson & Johnson Academy, the establishment of the Johnson & Johnson China Digital Innovation Center, and the creation of a global electrophysiology application and training center. (Business New Knowledge)

4. Zhuhai Zhongke Innovation Science Park Sets Sail to Build a New High Ground for Innovation in the Bay Area

Recently, the Zhuhai Zhongke Innovation Science Park, with a total investment of over 2 billion yuan, has officially commenced operations and welcomed the signing and landing of 11 major scientific and technological achievement transformation projects. This provincial key construction project, with a total construction area of approximately 220,000 square meters, aims to build a cross-regional collaborative innovation model of "Shenzhen R&D + Zhuhai Transformation," injecting strong momentum into the Guangdong-Hong Kong-Macao Greater Bay Area's scientific and technological innovation landscape, and creating a benchmark platform for the transfer and transformation of scientific and technological achievements and industrial incubation. The 11 major achievement transformation projects signed at the event focus on strategic emerging industries such as biomedicine, medical devices, artificial intelligence, and new materials, with several technologies achieving breakthroughs in "chokepoint" areas. The Sino-European Innovation Medicine and Health Research Center will be located in the park, achieving breakthroughs in the localization of gene-editing tools and large-scale preparation of viral vectors, which are "chokepoint" areas. (Yangcheng Evening News)

5. Philips Partners with Four ICU Giants

Recently, Philips announced strategic partnerships with four leading intensive care companies: ventilator giant Dräger, Hamilton Medical, Getinge, and infusion pump industry leader B.Braun Melsungen AG. This collaboration aims to optimize and upgrade hospital operations, comprehensively enhancing the in-hospital experience for both patients and clinicians. The core of this partnership lies in the Service-oriented Device Connectivity (SDC) standard. This standard breaks down barriers between different brands of medical devices and platforms, enabling interoperability. SDC establishes a universal "language" system for SDC-certified medical devices, allowing clinicians to conveniently access and utilize data generated by technologies from different device manufacturers without being troubled by compatibility issues. (Medical Field Insights)

6. The UK Plans to Introduce EU High-Risk IVD General Specifications

Recently, the UK government announced plans to revise the "Medical Device Regulations 2002" to incorporate the EU's high-risk IVDR Common Specifications (EU Common Specifications) into the Great Britain jurisdiction, while abolishing the CTDA (Coronavirus Test Device Approvals) process for COVID-19 test kits. The revision targets high-risk (Class D) IVDs such as HIV, hepatitis B/C/D, syphilis, blood typing, tissue typing, and COVID-19 testing. A temporary expedited CTDA process will be introduced, applicable only to COVID-19 devices with existing CE marks that comply with EU CS requirements. Long-term goals include streamlining regulation, aligning with EU standards, enhancing patient safety, and promoting medical technology innovation. (CACLP In Vitro Diagnostics Information)

7. R&D Design Services Accelerate the Clinical Transformation of Medical Research Achievements

The R&D of medical devices is a complex and rigorous process, involving multiple aspects such as technology, regulations, and clinical practices. Orschda boasts a 20,000㎡ science and innovation center and has established a Medical Device Research Institute dedicated to the clinical transformation of medical research achievements. It possesses a high-level, international, multidisciplinary professional team proficient in the entire process of R&D, regulations, clinical trials, registration, and production, capable of developing and producing various complex innovative products. The company has accumulated extensive project experience and industry resources, building a standardized, regulated, and digitalized full-process service system. It provides one-stop services ranging from preliminary market research, product concept generation, product design and development to prototype production and testing. To date, Orschda has had over 200 projects enter the review stage, more than 100 projects under development, with a 100% success rate in transformation. (Orschda Compilation)

8. Southern Yuan Bio Completes Tens of Millions of Yuan in Series A Financing

Recently, Nanjing Southern Element Biotechnology Co., Ltd., an innovative medical device company, announced the completion of a multi-million yuan Series A financing round. This round was led by Fosun Health Capital with participation from Hotang Ventures. The funds will primarily be used for the registration applications and industrialization layout of its core product—the revolutionary biopolymer hemostatic material Hemoadhican® (HD) series medical devices—with the China National Medical Products Administration and the U.S. Food and Drug Administration. Relying on its self-developed biopolymer synthesis hemostasis technology, Southern Element Biotech has successfully broken through traditional limitations. The HD material, through its unique spatial topological structure design, enables precise intraoperative free filling, shaping, and trimming, perfectly adapting to both open and minimally invasive surgical scenarios. It possesses rapid second-level hemostatic capabilities without relying on the patient's coagulation function, making it equally effective for patients undergoing anticoagulation therapy. (VcBeat)